Abstracts tagged "Effective"

Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Stanley B Cohen², Morton Scheinberg³, Tamas Shisha⁴, Dmitrij Kollins⁴, Peijuan Zhu⁵, Liyi Cen⁴, Alan J. Kivitz⁶, Andra Rodica Balanescu⁷, Juan J. Gomez-Reino⁸ and Hans-Peter Tony⁹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Metroplex Clinical Research Centre, Dallas, TX, ³Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁴Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, ⁵Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ⁸BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, ⁹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Rongqiang Zhang¹, Puwei Yuan², Jia Li³, Bo Dong¹, Wulin Kang³, Stephanie Hyon⁴, Raveendhara R. Bannuru⁵, William F. Harvey⁴ and Chenchen Wang⁴, ¹Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, ²Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, ³Shaanxi University of Chinese Medicine, Xianyang, China, ⁴Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁵Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
Abstract Number: 1205 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Low-Dose Radiation Therapy on Symptoms in Knee Osteoarthritis: First Results of a Triple Blinded, Randomized Controlled Trial
E.A.M. Mahler¹, M.J.M Minten¹, M.M. Leseman-Hoogenboom², P.M.P. Poortmans², S.S. Boks³, J.W.J. Bijlsma⁴, F.H.J. van den Hoogen^1,5, A.A. Den Broeder^1,5 and C.H.M. van den Ende^1,5, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Radiation Therapy, Radboud university medical centre, Nijmegen, Netherlands, ³Radiology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: Previous research in animal osteoarthritis (OA) has shown that low-dose radiation therapy (LD-RT) exerts anti-inflammatory effects, but a systematic review concluded that the evidence…
Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting
Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis
Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan
Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…
Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study
Maria Chiara Gerardi¹, Alberto Batticciotto², Rossella Talotta¹, Maria Chiara Ditto¹, Fabiola Atzeni² and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…
Abstract Number: 14 • 2016 ACR/ARHP Annual Meeting
Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar
Maria Jezabel Haye Salinas¹, Soledad Retamozo², Alejandro Alvarellos³, Francisco Caeiro⁴, Juan Pablo Pirola⁴, Diego Baenas¹, María Celina de La Vega⁵, Gustavo Casado⁶, Gimena Gomez⁷, Javier Roberti⁸, Osvaldo Luis Cerda⁹, Ignacio Javier Gandino¹⁰, Ana Quinteros¹¹, Ida Exeni^6,12, Juan Manuel Bande¹³, Juan Carlos Barreira¹⁴, Carla Gobbi¹⁵, Analia Alvarez¹⁶, Amelia Granel¹⁷, Alejandra Peluzzon¹⁸, Ana Capuccio¹⁹, Romina Nieto²⁰, Rossana Quintana²¹, Eduardo Mussano²², Santiago Scarafia²³, Carolina Costi²⁴, Mercedes De La Sota²⁵, Monica Patricia Diaz²⁶, Edson Javier Velozo²⁷, Santiago Aguero²⁸, Cristina Battagliotti²⁹, Sidney Soares de Souza³⁰, Emilia Cavillon³¹, Analia Bohr³², Andrea Smichowski³³, Daniela Vidal³⁴, Dora Pereira³⁵, Liliana Martinez³⁶, Luis Somma³⁷, Marta Zalazar³⁸, Pablo Finucci Curi³⁹, Leandro Carlevaris⁴⁰, Guillermo Berbotto⁴¹ and Veronica Saurit⁴, ¹Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁵Sociedad Argentina de Reumatología, CABA, Argentina, ⁶Sociedad Argentina de Reumatologia, CABA, Argentina, ⁷Sociedad Argentina de Reumatología, Buenos Aires, Argentina, ⁸SAR, CABA, Argentina, ⁹IREP, CABA, Argentina, ¹⁰Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Centro Integral Reumatológico, Tucuman, Argentina, ¹²Sanatorio Parque, Cordoba, Argentina, ¹³Hospital Tornú, CABA, Argentina, ¹⁴Rheumatology Unit, Hospital Britanico de Buenos Aires, CABA, Argentina, ¹⁵Rheumatology, Sanatorio Allende de Córdoba, Cordoba, Argentina, ¹⁶Hospital Penna, Bahía Blanca, Argentina, ¹⁷Centro Platense de Reumatología, La Plata, Argentina, ¹⁸Hospital Clínica José de San Martín, CABA, Argentina, ¹⁹Hospital Cesar Milstein, CABA, Argentina, ²⁰Hospital Provincial, Rosario, Argentina, ²¹Sanatorio Parque, Rosario, Argentina, ²²Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, ²³Hospital Bernardino Rivadavia, CABA, Argentina, ²⁴Hospital San Martín, LaPlata, Argentina, ²⁵Consultorios, Bahia Blanca, Argentina, ²⁶Hospital Zonal Bariloche, Bariloche, Argentina, ²⁷Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁸Sanatorio Pasteur, Catamarca, Argentina, ²⁹Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ³⁰Ramallo 1851, REUMAR, CABA, Argentina, ³¹Consultorio, Cordoba, Argentina, ³²Hospital de Rehabilitación Rocca, CABA, Argentina, ³³Atención Integral de Reumatología, CABA, Argentina, ³⁴Hospital de Niños de Córdoba, Córdoba, Argentina, ³⁵Centro Raquis, Buenos Aires, Argentina, ³⁶Hospital Fernandez, CABA, Argentina, ³⁷SOMMA, Buenos Aires, Argentina, ³⁸Hospital Pirovano, CABA, Argentina, ³⁹Centro Médico Mitre, Entre Rios, Argentina, ⁴⁰IARI, CABA, Argentina, ⁴¹Sanatorio Británico, Rosario, Argentina
Background/Purpose: to analyze failure predictors to anti-tumor necrosis (TNF) therapy in patients who have switched these drugs during chronic arthritis treatment. Methods: BIOBADASAR is a…
Abstract Number: 244 • 2016 ACR/ARHP Annual Meeting
Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease
Yiwen Wang¹, Dai Gao¹, Gui Luo², Kunpeng Li¹, Zheng Zhao¹ and Jian Zhu¹, ¹Rheumatology, Chinese PLA General Hospital, Beijing, China, ²Chinese PLA General Hospital, Beijing, China
Background/Purpose: Good response could be observed after applying glucocorticoids (GCs) in patients with IgG4-related disease (IgG4-RD), however, the risk of disease relapse was reported relatively…
Abstract Number: 1622 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Iguratimod in Patients with Active Rheumatoid Arthritis: A Multicenter, Single-Arm, Open-Label, Real World Study
Rong Mu, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: To evaluate the safety and efficacy of iguratimod, a novel DMARD, in active rheumatoid arthritis patients. Methods: Patients with active rheumatoid arthritis received iguratimod…
Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA Study Group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 713 • 2015 ACR/ARHP Annual Meeting
Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Juergen Braun⁴, Gustavo Citera⁵, Filip van Den Bosch^6,7, Ronald Pedersen⁸, Randi Bonin⁹, Heather Jones¹⁰, Lisa Marshall¹⁰, Sameer Kotak¹¹, Isabelle Logeart¹², Bonnie Vlahos¹³, Jack F Bukowski⁹ and Walter Maksymowych¹⁴, ¹Rheumatology Department, Hôpital Cochin, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹Clinical Affairs, Pfizer, Collegeville, PA, ¹⁰Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Medical Affairs, Pfizer, France, Paris, France, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), clinical signs/symptoms and MRI-measured inflammation were evaluated in patients with early, active non-radiographic…
Abstract Number: 750 • 2015 ACR/ARHP Annual Meeting
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
Jasvinder A. Singh¹ and Nipam Shah², ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Belimumab is a new approved treatment option for patients with lupus. Our objective was to perform a systematic review of benefits and harms of…
Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
R Westhovens¹, Rieke Alten², Dace Pavlova³, Favio Enríquez-Sosa⁴, Minodora Mazur⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³LTD M & M Centrs, Carnikava, Latvia, ⁴CLINSTILE, S.A. DE C.V, Mexico, Mexico, ⁵IMSP Institul de Cardiologie, Chisinau, Moldova, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
Abstract Number: 1049 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
Arthur Kavanaugh¹, Lucia Ponce², Regina Cseuz³, Olga Reshetko⁴, Mykola A Stanislavchuk⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹University of California San Diego, La Jolla, CA, ²Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ³Revita Reumatologiai Rendelo, Budapest, Indonesia, ⁴Regional Clinical Hospital, Saratov, Russia, ⁵Vinnitsa Regional Clinical Hospital n.a. Pirogov, Vinnitsa, Ukraine, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
Abstract Number: 2049 • 2015 ACR/ARHP Annual Meeting
Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases
Huifeng Yun¹, Fenglong Xie², John Baddley³, Kevin L. Winthrop⁴, Lang Chen⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵University of Alabama at Bimingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The live herpes zoster (HZ) vaccine is effective in healthy older people to reduce the incidence and burden of HZ. Recent results from a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].